RK Smiley Research Grant Program
The RK Smiley Research Grant program provides start up grants aimed at pilot projects expected to lead to larger follow-up studies funded by CIHR or other grant funding agencies.
Established in 2011 to mark the Fortieth Anniversary of the Canadian Hematology Society’s service and to support hematology practitioners in Canada, this award is named in honour of the CHS Founding President, Dr. R. Kennedy Smiley, who was also instrumental in founding the University of Ottawa’s medical school. Many impressive submissions from across Canada have been received in response to the announcement of this new research grant program since its inception.
The CHS Executive Committee is very pleased to announce that the deadline for submissions to the R K Smiley Award is 1800h on Monday, March 1, 2021. Decisions will be announced in May 2021.
Eligibility Criteria: Applicants may be clinicians or scientists with a project relevant to the field of hematology and must be members of the Canadian Hematology Society. Preference will be given to groups who will benefit maximally from the limited start up funds.
RK Smiley Research Grant Winners
2020
-
2020
Dr. Clinton Campbell
DEEPHEME: An Innovative Deep Learning Platform to Improve Diagnosis in Hematology
McMaster University
-
2020
Dr. Courtney Jones
Identification of Glutathionylated Proteins in the Mitochondria of Leukemia Stem Cells
Unity Health Network
2019
-
2019
Dr. Miriam Kimpton
Thromboprophylaxis with apixaban in polycythemia vera and JAK2- positive essential thrombocythemia patients: A pilot randomized controlled trial assessing feasibility.
University of Ottawa
-
2019
Dr. Kevin Kuo
A multicenter study evaluating the reliability and validity of the Rowland Universal Dementia Assessment Scale (RUDAS) and predictors of RUDAS performance in adults with Sickle Cell Disease
University of Toronto
2018
-
2018
Dr. Christine Cserti-Gazdewich
The Monocyte Monolayer Assay: Enhancing Care for the Untrasfusables
Blood Transfusion Medicine, Toronto General Hospital
-
2018
Dr. Robert Kridel
Identifying new therapeutic targets for double-hit lymphoma using CRISPR-Cas screens
Medical Oncology & Hematology Princess Margaret Cancer Centre, Toronto
2017
-
2017
Dr. Steven Chan
Genome-Wide Identification of Synthetic Lethal Genes against TET2 Mutations in Acute Myeloid Leukemia (AML)
Princess Margaret, University Health Network, Toronto
-
2017
Dr. Bertrand Routy
Influence of gut microbiota on anticancer activity of immuno-therapeutic strategies in patients with multiple myeloma
McGill University, Montreal
2016
-
2016
Dr. Signy Chow
Next Generation Sequencing of circulating tumor DNA (ctDNA) for Minimal Residual Disease (MRD) and Monitoring of Clonal Evolution in Multiple Myeloma (MM).
University Health Network, Toronto
-
2016
Dr. Ziad Solh
Neonatal Outcomes after Transfusion of ABO Non-Identical Blood (Neo-ABO)
McMaster University, Hamilton, Ontario
2015
-
2015
Dr. Yulia Lin
Setting the benchmark metric for red blood cell transfusion (RBC) to allow for assessment of optimal transfusion care: A pilot quality project at 10 hospitals.
Sunnybrook Health Sciences Centre and University Health Network, Toronto
-
2015
Dr. Ana Nijnik
Genome-wide Identification of p53-Regulated Genes in Hematopoietic Stem and Progenitor Cells
McMaster University, Hamilton, Ontario
2014
-
2014
Dr. Geerte van Sluis
A Pilot Study Investigating the Significance of Novel Factor Xa Inhibitor Interactions with Dexamethasone-Containing Regimens for Multiple Myeloma
University of British Columbia
-
2014
Dr. Paul Spagnuolo
Mitophagy in the development of leukemia stem cell mitochondrial phenotype
University Waterloo, School of Pharmacy
2013
-
2013
Dr. Brent Williams
Treatment of AML xenografted mice with CD16+NK-92 and anti-CD123 antibody
Princess Margaret Hospital, Toronto
-
2013
Dr. Isaac Odame
White matter integrity and neurocognition in sickle cell patients
University of Toronto
-
2013
Dr. Nathalie A. Johnson
The role of FAZ mutations in chemotherapy-resistant lymphomas
McGill University, Montreal
2012
-
2012
Dr. Hubert Tsui
“Sensing” Hematopoiesis
University of Toronto
-
2012
Dr. Christian Steidl
Prognostic markers in relapsed Hodgkin lymphoma
BC Cancer Centre
-
2012
Dr. Michael Rauh
Myeloid-derived suppressor cells as potential novel mediators of Factor VIII tolerance in Hemophilia A
Queen’s University, Kingston, Ontario